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A B S T R A C T
Genetic frontotemporal dementia is most commonly caused by mutations in the progranulin (GRN),
microtubule-associated protein tau (MAPT) and chromosome 9 open reading frame 72 (C9orf72) genes.
Previous small studies have reported the presence of cerebral white matter hyperintensities (WMH) in genetic
FTD but this has not been systematically studied across the diﬀerent mutations. In this study WMH were assessed
in 180 participants from the Genetic FTD Initiative (GENFI) with 3D T1- and T2-weighed magnetic resonance
images: 43 symptomatic (7 GRN, 13 MAPT and 23 C9orf72), 61 presymptomatic mutation carriers (25 GRN, 8
MAPT and 28 C9orf72) and 76 mutation negative non-carrier family members. An automatic detection and
quantiﬁcation algorithm was developed for determining load, location and appearance of WMH. Signiﬁcant
diﬀerences were seen only in the symptomatic GRN group compared with the other groups with no diﬀerences in
the MAPT or C9orf72 groups: increased global load of WMH was seen, with WMH located in the frontal and
occipital lobes more so than the parietal lobes, and nearer to the ventricles rather than juxtacortical. Although no
diﬀerences were seen in the presymptomatic group as a whole, in the GRN cohort only there was an association
of increased WMH volume with expected years from symptom onset. The appearance of the WMH was also
diﬀerent in the GRN group compared with the other groups, with the lesions in the GRN group being more
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similar to each other. The presence of WMH in those with progranulin deﬁciency may be related to the known
role of progranulin in neuroinﬂammation, although other roles are also proposed including an eﬀect on blood-
brain barrier permeability and the cerebral vasculature. Future studies will be useful to investigate the
longitudinal evolution of WMH and their potential use as a biomarker as well as post-mortem studies
investigating the histopathological nature of the lesions.
1. Introduction
Frontotemporal dementia (FTD) is an umbrella term used to denote
a group of neurodegenerative disorders aﬀecting principally the frontal
and temporal lobes. It is a highly heritable disorder with approximately
a third of cases being caused by mutations in predominantly three
genes: progranulin (GRN), microtubule associated protein tau (MAPT)
and chromosome 9 open reading frame 72 (C9orf72) (Rohrer et al.,
2015; Rohrer and Warren, 2011). Whilst the clinical features of GRN-,
MAPT- and C9orf72-associated FTD largely overlap, the underlying
molecular processes leading to that phenotypic endpoint are fundamen-
tally diﬀerent (Lashley et al., 2015).
To date, most antemortem studies of familial FTD have focused on
changes in gray matter, but some types of FTD are known to be
associated with white matter pathology. Such changes may be seen by
magnetic resonance imaging (MRI) e.g. cerebral white matter hyper-
intensities (WMH). These WMH are usually identiﬁed on T2, FLAIR or
PD-weighted MRI and reﬂect an abnormal tissue fat/water ratio. They
are commonly seen in healthy aging and more extensively in patients
with neuroinﬂammatory disorders or small vessel cerebrovascular
disease. Research into the link between WMH and other forms of
dementia has been ongoing for some time with lesions seen particularly
in those with vascular dementia as well as being commonly associated
with Alzheimer's disease (Snyder et al., 2015). In such cases of
dementia lesions are generally felt to represent ischaemic damage
(Wardlaw et al., 2015). WMH are less commonly seen in FTD but recent
small studies have reported their presence in some cases, particularly in
those with GRN mutations (Caroppo et al., 2014; Paternicò et al., 2016;
Pietroboni et al., 2011). However, a detailed investigation in a large
cohort has yet to be performed.
Many studies of WMH in dementia use visual rating scales, manual
or semi-automated segmentation methods (Yoshita et al., 2005).
However, for large cohorts time consuming operator-dependent seg-
mentation becomes unfeasible. Automated segmentation methods have
therefore been developed for extracting WMH from either FLAIR or T2-
weighted images. We have previously developed a methodology for
automatically segmenting WMH through modelling of unexpected
observations in MR images (Sudre et al., 2015). In order to investigate
the presence of WMH in FTD further we used this methodology on data
from the Genetic FTD Initiative (GENFI) (Rohrer et al., 2015) which
investigates symptomatic and at-risk members of families with muta-
tions in GRN, MAPT and C9orf72.
2. Methods
2.1. Demographics
The ﬁrst phase of the GENFI multicentre cohort study comprised 13
research centres across Europe and Canada (www.genﬁ.org.uk) (Rohrer
et al., 2015). Local ethics committees gave approval for the study at
each site and all participants gave written informed consent prior to
enrolment. Between January 2012 and April 2015 365 participants
were recruited into GENFI, of whom 190 underwent both 3D T1 and 3D
T2 acquisitions on a 3T MRI scanner. Ten scans did not pass quality
control (excessive motion) and so 180 were used for the ﬁnal analysis.
Four scanner types were used with protocols designed at the outset of
the study to minimise discrepancies between scanners. Of the 180
participants included in the study, 43 were symptomatic (7 GRN, 13
MAPT and 23 C9orf72) and 61 were presymptomatic mutation carriers
(25 GRN, 8 MAPT and 28 C9orf72) with a further 76 participants found
to be mutation negative non-carriers (and therefore acting as a control
group). Demographics for the cohort are described in Table 1.
2.2. Imaging analysis
Whilst FLAIR images have become the standard for the study of
WMH due to good separation between CSF and lesion signal, T2-
weighted images may also be used, although are more challenging to
segment due to the proximity in signal signature between lesions and
CSF. In order to segment the WMH in the GENFI dataset (which
includes 3D T2-weighted images but not FLAIR) our previously
described algorithm (Sudre et al., 2015) was adapted to address the
speciﬁc challenges that arise in the use of T2-images. In this model an
adaptive hierarchical three-level multivariate Gaussian mixture model
(GMM) using both T1 and T2 weighted images is used to model both
normal and unexpected signal observations. At a ﬁrst level, inliers (I)
and outliers (O) are segmented and a priori information on their
location is progressively introduced by smoothed maps of typicality
measures (Van Leemput et al., 2001). At the second level, anatomical
information is introduced through statistical atlases so as to model the
diﬀerent biological tissues (gray matter, white matter, CSF and other
non-brain structures) for both the inlier and outlier parts of the model.
The appropriate number of Gaussian components necessary to model
the diﬀerent tissues and their parameters are presented at the third
level of the hierarchy. In this study, the anatomical atlases are obtained
as a result of a label fusion algorithm (Cardoso et al., 2015): Gaussian
Table 1
Demographics of the cohort and summary of WMH volumes for each group.
NC C9orf72 GRN MAPT
PS S PS S PS S
Number Male:female 76 (51:25) 28 (16:12) 23 (5:18) 24 (14:10) 8 (4:4) 8 (7:1) 13 (4:9)
Mean (SD) age (years) 48.2 (15.1) 44.4 (11.3) 66.1 (6.7) 45.7 (12.3) 65.7 (6.6) 38.0 (11.5) 57.9 (8.2)
Mean (SD) TIV (ml) 1523 (139) 1582 (164) 1634 (135) 1535 (128) 1512 (127) 1485 (91) 1555 (120)
WMH (ml) Mean 0.80 0.81 0.93 0.76 2.63 0.43 1.32
Median 0.49 0.63 0.72 0.46 0.75 0.41 0.60
Range [0.04 6.56] [0.08 2.59] [0.16 2.46] [0.11 4.30] [0.63 7.45] [0.14 0.87] [0.02 5.02]
IQR [0.32 0.70] [0.24 1.24] [0.23 1.50] [0.23 0.71] [0.65 5.08] [0.18 0.64] [0.34 1.09]
SD 1.17 0.70 0.71 0.94 2.81 0.27 1.69
NC - Non-carriers; PS - Presymptomatic; S - Symptomatic; SD - Standard deviation; TIV - Total intracranial volume; IQR - Interquartile range.
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components parameters are optimised via an expectation-maximisation
(EM) algorithm that incorporates contextual constraints with the
application of a Markov Random Field. In order to determine the
number of Gaussian components required to model the data, splitting
and merging operations are tested at the third level of the hierarchy. To
ensure a balance between model accuracy and ﬁt, the Bayesian
Information Criterion is used to assess if a model change should be
accepted or not. The list of model changes to test is determined each
time the model complexity evolves and the algorithm stops once all of
these changes have been tested and rejected. Once the data model has
been determined and optimised, it can be used to segment WMH. The
characteristics of the healthy appearing WM are used as a reference to
select the voxels classiﬁed as outliers that could be considered as lesion.
More speciﬁcally, the probabilistic maps of outliers are multiplied
Fig. 1. Example of the location patient-speciﬁc scheme for the three orientations. From left to right: 1st column: T2-weighted image with overlayed lesion segmentation; 2nd column:
lobar separation; 3rd column: layer discretisation. The corresponding lesion frequency per zone is given in the inset image at the bottom.
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voxelwise by a weight wn deﬁned as:
where yn indicates the intensity at voxel n, and μIWM and σIWMrefer to
the mean and standard deviation of the white matter inliers (IWM). The
anatomical tissue segmentation result is then combined with a brain
parcellation to expunge the probabilistic map of voxels whose intensity
reﬂect partial volume eﬀect between the main tissues and the ventri-
cular lining. In particular, the ventricular segmentation is morphologi-
cally dilated and voxels classiﬁed as lesion removed from this area.
In determining WMH location, biases may be introduced if non-
linear registrations are applied to images with lesions (Chard et al.,
2010) or if absolute distance to the ventricular lining that does not
account for atrophy is chosen to diﬀerentiate between lesion locations
(Woong Kim et al., 2008). Additionally, in the case where few lesions
are present, voxelwise analyses may prove prone to noise (van der Lijn
et al., 2012). Therefore, to study the lesion distribution in the brain, a
patient-speciﬁc location scheme was applied dividing the white matter
into regions reﬂecting their distance to the ventricular surface and
lobes. To separate lobar regions, a parcellation of the gray matter was
used to divide it into frontal, parietal, occipital and temporal lobes for
the left and the right hemisphere. Euclidean distance from these deﬁned
lobes was then used to separate the WM. Basal ganglia were considered
as a separate region and the infratentorial region excluded from the
analysis. In order to avoid using absolute values that would be biased
by brain atrophy, normalised distance maps between ventricular sur-
face and cortical sheet were computed using the solution to the Laplace
equation as described by Yezzi et al. (Yezzi and Prince, 2002) and
discretised into four equidistant layers as suggested by Kim et al. (Kim
et al., 2008) with layer 1 being nearest to the ventricle and layer 4
being juxtacortical. Ultimately the white matter domain was separated
into 36 zones (made up of 9 regions and 4 layers within each region).
To visualise the zonal separation, a bullseye plot was used in which the
regions were encoded by the angular position and the layers were given
by the radial position, with the distance to the ventricular surface
increasing with the distance from the plot centre. The zonal character-
istics such as the proportion of the zone aﬀected by WMH can then be
colour-encoded in the plot. With this representation, complex 3D
information was thus summarized and gathered into a planar systema-
tic infographic. Fig. 1 presents an illustration of the zonal separation
and the lesion segmentation for a case of a symptomatic subject with a
GRN mutation.
2.3. Statistical analyses
Stata v14 was used for all statistical analyses. Due to the skewness of
the data, both global and zonal volumetric WMH values were log-
transformed before analysis.
For the global volumes analysis, linear regression was performed
considering WMH volume as the dependent variable and adjusting for
age, gender, total intracranial volume (TIV), years from expected
symptom onset [see Rohrer et al., 2015 for more details] and scanner
type. A diﬀerent adjustment was allowed for their mutation status
[presymptomatic vs symptomatic] and genetic group [GRN vs C9orf72
vs MAPT]. A similar analysis was also performed for the diﬀerent lobes
and layers.
In order to exclude any confounding inﬂuence of cardiovascular risk
factors, the eﬀects of hypertension, hypercholesterolaemia and diabetes
mellitus on WMH volumes were assessed separately for each mutation
group. None showed any signiﬁcant association and were therefore not
further included as covariates in the model.
For the location analysis, the zonal standardised log-volumes were
used as dependent variables and corrected separately for age, gender,
TIV, scanner type and again a diﬀerent adjustment was allowed for
mutation status and genetic group.
A further analysis was performed on the distribution of lesion
intensities, which (due to the adopted model for lesion segmentation)
can be expressed as a standardised intensity or Z-score to the normal
appearing WM tissue and allows groups to be distinguished. Although
T2-weighted MR acquisition does not provide a quantitative measure-
ment of the damage to the WM, such an intensity analysis provides an
estimate of the appearance of the lesions i.e. how similar the hyper-
intensities of diﬀerent lesions are. In order to avoid including partici-
pants that present with enlarged perivascular spaces as signal hyper-
intensities in the WM only participants with at least 0.5 mL of WMH
were selected for this analysis.
3. Results
3.1. Global volumes analysis
WMH volumes are shown in Table 1. Age was signiﬁcantly
associated with WMH volumes (p= 0.0005) as was TIV (p= 0.003).
Mean adjusted back-transformed results with conﬁdence intervals and
p-values for group comparisons are shown in Table 2: symptomatic GRN
subjects had a signiﬁcantly higher mean global WMH volume than
presymptomatic GRN cases and noncarriers, as well as more than the
symptomatic MAPT and C9orf72 groups. By contrast, no signiﬁcant
Table 2
Mean adjusted WMH values corrected for age, sex, TIV, scanner type and estimated average years before onset. Volumetric values are given in ml.
Non-carriers Carriers Presymptomatic Symptomatic p-Values
Mean CI Mean CI Mean CI
0.50 [0.40 0.62] C9orf72 0.50 [0.35 0.71] 0.44 [0.28 0.67] NC vs PS 0.99
NC vs S 0.60
PS vs S 0.87
GRN 0.56 [0.39 0.81] 1.51 [0.77 2.94] NC vs PS 0.60
NC vs S 0.0030
PS vs S 0.012
MAPT 0.53 [0.27 1.06] 0.59 [0.34 1.02] NC vs PS 0.87
NC vs S 0.60
PS vs S 0.87
p-values C9orf72 vs GRN 0.86
C9orf72 vs MAPT 0.99
GRN vs MAPT 0.86
C9orf72 vs GRN 0.0048
C9orf72 vs MAPT 0.67
GRN vs MAPT 0.012
CI - Conﬁdence interval.
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diﬀerence was observed between the presymptomatic GRN cases and
the noncarriers. Furthermore, no signiﬁcant diﬀerences were seen
between the symptomatic (or presymptomatic) C9orf72 or MAPT
groups and noncarriers.
For visualisation purposes, the beeswarm plot of the WMH volumes
for the diﬀerent groups is presented in Fig. 2 along with a colour-coded
representation of the eﬀect size when comparing the diﬀerent groups.
The presymptomatic groups include a heterogeneous population
including some participants near to the mean age of onset in the family
and others more distant. In order to evaluate the change in WMH with
disease progression, disjoint regression models were used to analyse the
relationship between WMH volumes and years from expected age of
onset in each mutation group, correcting for gender, scanner type and
TIV. An association between WMH volume and years from expected age
of onset was only signiﬁcant in the GRN group (p= 0.002) [MAPT
group (p= 0.286), C9orf72 group (p= 0.214)].
3.2. Location analysis
Beeswarm plots of the raw volumes of lesion and eﬀect size
calculated for the mean of log-transformed volumes adjusted for
gender, age, TIV, scanner type are presented in Fig. 3 for the four
layers and Fig. 4 for the diﬀerent regions. Signiﬁcant diﬀerences were
seen in the symptomatic GRN group compared with noncarriers in the
three layers nearest the ventricle with no signiﬁcant diﬀerences in the
most juxtacortical layer (Fig. 3): layer 1: p= 0.0209; layer 2:
p= 0.0005; layer 3: p= 0.0099; layer 4: p= 0.3223. Signiﬁcant
diﬀerences were also seen in the symptomatic GRN carriers compared
with the symptomatic MAPT and C9orf72 carriers (layer 1 for MAPT,
and layers 2, 3 and 4 for C9orf72): layer 1: p= 0.0457 (MAPT), 0.1345
(C9orf72); layer 2: p= 0.0539 (MAPT), p= 0.0147 (C9or72); layer 3:
p= 0.1314 (MAPT), 0.0094 (C9orf72); layer 4: p= 0.3882 (MAPT),
p= 0.0248 (C9orf72). Lastly, signiﬁcant diﬀerences were also seen
between the symptomatic and presymptomatic GRN carriers for layers 2
and 3: layer 1: p= 0.0691; layer 2: p= 0.0102; layer 3: p= 0.0348;
layer 4: p= 0.4404. No signiﬁcant diﬀerences were seen between other
groups. For the regions, signiﬁcant diﬀerences between the sympto-
matic GRN group and noncarriers were seen in the frontal lobe
(p= 0.0020) and the occipital lobe (p= 0.0072) as well a smaller
diﬀerence in the parietal region (p= 0.0252) with no signiﬁcant
diﬀerence observed in the temporal lobe (p= 0.6972) (Fig. 4). Sig-
niﬁcant diﬀerences were also observed between the symptomatic GRN
carriers and the symptomatic MAPT and C9orf72 carriers in the frontal
and occipital lobes: frontal: p= 0.0170 (MAPT), 0.0040 (C9orf72);
occipital: p= 0.0203 (MAPT), 0.0196 (C9orf72). Furthermore, sympto-
matic GRN carriers had signiﬁcantly more WMH than presymptomatic
carriers in the frontal and occipital lobes: p= 0.0184 (frontal), 0.0105
(occipital). Lastly, both MAPT and GRN symptomatic carriers presented
signiﬁcantly more WMH in the parietal lobe than the symptomatic
C9orf72 carriers: p= 0.0117 (GRN), 0.0337 (MAPT). None of the
diﬀerences were signiﬁcant in the temporal lobe. In the basal ganglia,
signiﬁcantly less WMH were detected in the symptomatic GRN and
MAPT cases compared with noncarriers (p= 0.0005 (GRN),
p= 0.0002 (MAPT)) and with symptomatic C9orf72 carriers
(p= 0.0079 (GRN), p= 0.0055 (MAPT)). A symptomatic diﬀerence
was also seen between the GRN symptomatic and presymptomatic
carriers (p= 0.0016) with other group comparisons nonsigniﬁcant. The
location analyses are summarized in the bullseye plots in Fig. 5 which
encode the mean adjusted standardised value for each zone.
3.3. Analysis of lesion appearance
For the 97 subjects whose WMH volumes were higher than 0.5 mL,
histograms of lesion intensities standardised with respect to the normal
appearing white matter as obtained by the segmentation model were
averaged for each subgroup. Fig. 6 shows the corresponding histogram
bar plots. The distribution of lesion intensities in the symptomatic GRN
group was narrower than for the other groups suggesting greater
consistency of signal intensity in the lesions within this group. The
interquartile range of the lesion intensity Z-scores was used to
quantitatively assess this observation: the boxplot of IQR distributions
across groups is presented in Fig. 7 along with the eﬀect sizes calculated
for the adjusted mean corrected for lesion load and scanner type.
4. Discussion
Through the use of a lesion segmentation algorithm adapted to
segment WMH from 3D T1- and T2- weighted scans this study extends
previous work on WMH in genetic FTD to show their presence in a
symptomatic GRN mutation group only, and not in presymptomatic
participants nor in those with MAPT or C9orf72 mutations.
Furthermore, within the GRN group there was an association of
increased WMH volume with disease progression. Diﬀerences were
seen in the symptomatic GRN group in all three analyses suggesting
global and local diﬀerences in WMH as well as diﬀerences in their
appearance.
At the regional level, the frontal lobe was particularly aﬀected by
WMH, consistent with previous ﬁndings (Paternicò et al., 2016).
However, we also found signiﬁcant diﬀerences in the occipital lobe,
and to a lesser extent in the parietal lobe. WMH were found in the three
most central layers, i.e. closest to the ventricles. It may well be that this
periventricular distribution represents a particular pathogenetic feature
of GRN mutations: progranulin deﬁciency has been shown to be
associated with blood-brain barrier dysfunction and increased perme-
ability (Jackman et al., 2013), which have been shown to be associated
with periventricular lesions (Haller et al., 2013). However, as well as
Fig. 2. Beeswarm plot of WMH volumes for the diﬀerent groups (left) and corresponding matrix of eﬀect size of pairwise comparisons.
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the load and location pattern, the intensity outlierness analysis showed
that the appearance of the lesions were also diﬀerent in the sympto-
matic GRN cases from the other groups. The small number of lesions
seen in other groups with increasing age are likely to represent small
vessel cerebrovascular disease, and therefore the diﬀerent appearance
of the lesions in the GRN group may be representative of a non-
ischaemic origin. Progranulin has been shown to play a key role in
regulating wound repair and inﬂammation, including aﬀecting tumor
necrosis factor alpha signalling (Tang et al., 2011), and progranulin
deﬁciency is known to promote neuroinﬂammation (Martens et al.,
2012): therefore it may be that the lesions seen in these patients are
inﬂammatory in nature. Further evidence for active neuroinﬂammation
in GRN carriers comes from studies of knockout GRN mouse models
which show increased microglial activation (Yin et al., 2010) and
increased levels of pro-inﬂammatory cytokines (Yin et al., 2010), and of
blood cytokine levels in human GRN mutation carriers which display
elevated levels of TNF-α (Miller et al., 2013) and IL-6 (Bossù et al.,
2011).
Of note, fewer hyperintensities were observed in the basal ganglia
for both the symptomatic MAPT and GRN groups compared with the
other groups. The algorithm cannot diﬀerentiate between WMH and
enlarged perivascular spaces and in the basal ganglia hyperintensities
are likely to correspond to the latter rather than true WMH. It is unclear
why fewer are seen in these two groups although this may be related to
underlying atrophy of the basal ganglia which tends to be seen in the
GRN and MAPT groups to a greater extent than in the C9orf72 group
(Rohrer et al., 2015). It is less likely to represent a feature of the
underlying molecular processes although progranulin is known to
promote angiogenesis (Toh et al., 2013) and so progranulin deﬁciency
may potentially be associated with fewer perivascular spaces.
From a technical perspective, the use of this algorithm has
advantages over other methods of analysis of WMH location. The
application of a patient-speciﬁc systematic location scheme prevents
the WMH location pattern analysis from suﬀering from any biases due
to registration error or atrophy. Furthermore, the adapted algorithm for
T2-weighted images avoids the inclusion of elements at the border
4reyaL3reyaL2reyaL1reyaL
Fig. 3. Comparison between groups of the WMH load per layer (Layer 1 being nearest the ventricle, Layer 4 being juxtacortical). The ﬁrst row presents the beeswarm plots of WMH
volumes and the second row the corresponding matrices of eﬀect size in the group comparison.
Frontal Parietal Occipital Temporal Basal Ganglia
Fig. 4. Comparison between groups of the WMH load per lobe. The ﬁrst row presents the beeswarm plots of WMH volumes and the second row the corresponding matrices of eﬀect size in
the group comparison.
C.H. Sudre et al. NeuroImage: Clinical 15 (2017) 171–180
176
citamotpmyScitamotpmyserPsreirrac-noN
C9orf72
GRN
MAPT
Fig. 5. Bullseye representation of the zonal mean of adjusted standardised log-transformed volumes of WMH. Pink reﬂects a positive Z-score value while blue refers to a negative value.
citamotpmyScitamotpmyserPsreirrac-noN
C9orf72
GRN
MAPT
Fig. 6. Histogram distribution of T2 level of outlierness for the lesion segmentation in the diﬀerent groups. Outlierness is measured as a Z-score with respect to the normal appearing
white matter.
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between normal tissue that share a common intensity signature with
WMH on T2 images. Inherent to the use of T2-weighted images, it must
however be noted that in this WMH segmentation, enlarged perivas-
cular spaces are not distinguished from white matter lesions. An
additional limitation of the study lies in the fact that no information
is given on how individual lesions span multiple zones separated in
layers or in lobes. Further investigation of individual lesions both in
terms of extent and appearance through texture analysis would be of
interest.
The main strength of this study derives from the large cohort
available which enables comparisons not only between mutation
carriers and non-carriers but also between genetic groups and those
at diﬀerent stages of the disease process. Clinically, the presence of
WMH is an important sign of a potential GRNmutation in a patient with
familial FTD, whilst from a clinical trial point of view, it may be that
measurement of WMH load will be a useful biomarker, particularly in
trials targeting anti-inﬂammatory measures. In order to investigate this
further, the longitudinal change in load, location and appearance of
WMH, and their relationship to other neuroimaging measures of
atrophy or neuropsychological measures of disease severity and pro-
gression, in GRN carriers will be an important subject for future study.
Correlation of WMH burden with blood and CSF biomarkers of disease
intensity or progression in FTD, or with markers of inﬂammatory
processes, would also be helpful to investigate. In addition, post-
mortem studies of patients with GRN mutations will also be important
to understand what the WMH represent histopathologically, and their
relationship, if any, to markers of demyelination, neuronal loss,
neuroinﬂammation, small vessel disease, and TDP-43 pathology.
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